NewLink Genetics Corporation (NLNK) Given Buy Rating at Cantor Fitzgerald
NewLink Genetics Corporation (NASDAQ:NLNK)‘s stock had its “buy” rating restated by analysts at Cantor Fitzgerald in a note issued to investors on Thursday. They presently have a $26.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 177.78% from the stock’s previous close.
The analysts wrote, “Path Forward in Melanoma. Indoximod is expected to enter a pivotal Phase III trial in combination with both Keytruda and Opdivo, with a planned enrollment of 600 patients. The trial design aims to compare PD-1 monotherapy to combination treatments, with co-primary endpoints of overall survival (OS) and progression free survival (PFS).””
A number of other equities research analysts have also recently weighed in on the company. Bank of America Corporation assumed coverage on NewLink Genetics Corporation in a research note on Friday, October 13th. They set a “buy” rating and a $22.00 price objective for the company. ValuEngine cut NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Stifel Nicolaus upped their price objective on NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Robert W. Baird upgraded NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and increased their price target for the company from $8.00 to $22.00 in a research note on Friday, September 8th. Finally, Jefferies Group LLC upgraded NewLink Genetics Corporation from a “hold” rating to a “buy” rating and increased their price target for the company from $7.00 to $26.00 in a research note on Friday, September 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $25.83.
In other news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the business’s stock in a transaction dated Friday, October 6th. The shares were acquired at an average cost of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the acquisition, the insider now owns 7,857,732 shares of the company’s stock, valued at $80,541,753. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 13.70% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. acquired a new stake in NewLink Genetics Corporation during the third quarter worth about $963,000. The Manufacturers Life Insurance Company grew its holdings in NewLink Genetics Corporation by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 556 shares during the period. State Street Corp grew its holdings in NewLink Genetics Corporation by 1.2% during the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after acquiring an additional 4,630 shares during the period. Tudor Investment Corp ET AL acquired a new stake in NewLink Genetics Corporation during the second quarter worth about $286,000. Finally, PDT Partners LLC boosted its position in NewLink Genetics Corporation by 160.2% during the second quarter. PDT Partners LLC now owns 115,795 shares of the biotechnology company’s stock worth $851,000 after purchasing an additional 71,295 shares in the last quarter. 55.09% of the stock is currently owned by hedge funds and other institutional investors.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.